HHS announces new mental health initiative; cervical cancer rates decline; 100 million Johnson & Johnson vaccine doses held up.
HHS announced it is launching a council to address mental health and substance use issues that have increased throughout the pandemic, Medpage Today reports. The department will also give $3 billion in block grants to help fund state and local government behavioral health efforts. The Behavioral Health Coordinating Council will facilitate action-oriented approaches to addressing the country’s behavioral health needs, according to Rachel Levine, MD, the Assistant Secretary for Health. The council will include senior leadership across HHS divisions. Between September 2019 and September 2020, more than 90,000 drug overdose deaths were reported in the United States, an increase of around 20,000 compared with the same period a year prior.
Over the last 2 decades in the United States rates, of cervical cancers have fallen due largely to screening and the human papillomavirus (HPV) vaccine, the Associated Press reports. However, new study results also indicate the gains are offset by a rise in other tumors caused by HPV. By 2025, anal cancer and a rare type of rectal cancer caused by the virus may become more common than cervical cancers among older women. For men, oral sex has helped fueled more cases of mouth and throat cancers. HPV is the most common sexually spread infection in the United States; most infections cause no symptoms and go away without treatment. Some infections do develop into cancers, accounting for about 35,900 cases each year.
Emergent BioSolutions has revealed that 100 million Johnson & Johnson (J&J) vaccine doses are being help up over contamination concerns, The New York Times reports. The plant previously announced that a batch of 15 million J&J vaccines had been ruined in April. The chief executive of the company revealed the scope of the potential contamination in testimony before a House subcommittee. The plant, located in Baltimore, Maryland, housed unsanitary conditions including mold and peeling paint. Following the April revelations, operations were halted, but the company plans to resume production in a matter of days. All J&J doses administered in the United States were produced overseas.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen